曲格列酮抑制甲状腺滤泡状癌细胞生长  

Troglitazone inhibits growth of follicular thyroid carcinoma cell

作　　者：侯大卫[1] 沈美萍[1] 刘翠萍[1] 

机构地区：[1]南京医科大学第一附属医院普通外科,210029

出　　处：《江苏医药》2007年第6期583-586,共4页Jiangsu Medical Journal

基　　金：江苏省卫生厅135工程资助项目(2001031)

摘　　要：目的研究曲格列酮对甲状腺滤泡状癌细胞FTC-133生长的影响。方法将甲状腺滤泡状癌细胞FTC-133与不同浓度的曲格列酮共培养,4-甲基偶氮四唑蓝(MTT)法观察其对FTC-133细胞增殖的影响,流式细胞仪DNA定量法分析曲格列酮对FTC-133细胞细胞周期的影响,半定量RT-PCR法测定曲格列酮对甲状腺滤泡状癌细胞p27 mRNA表达的影响。结果曲格列酮可以抑制FTC-133细胞的增殖,并具有时间和浓度依赖性(P<0.05);曲格列酮作用后,甲状腺滤泡状癌细胞FTC-133的G0/G1细胞的比例增加(P<0.05);p27 mRNA的表达显著升高(P<0.05)。结论曲格列酮可以抑制甲状腺滤泡状癌细胞从G1期向S期的转化,从而抑制其增殖,曲格列酮可能成为治疗甲状腺滤泡状癌的一种选择。Objective To investigate the effects of troglitazone on the growth of follicular thyroid carcinoma cell line FTC-133. Methods Follicular thyroid carcinoma cell line FTC-133 was incubated with different concentrations of troglitazone and observed at different time points. The cell viabilities were measured with dimethylthiazol-diphenyltetrazolium bromide （MTT）assay, the cell cycles of the stimulated cells were analyzed by flow cytometry,and the expression of p27 mRNA was evaluated by semi-quantitative RT-PCR. Results Troglitazone inhibited the proliferation of thyroid carcinoma cells in dose- and time-dependent pattern （P〈0. 05）. After treated by troglitazone, the proportion of cells in G0/G1 phase increased significantly（P〈0.05）, and the p27 mRNA expression was up-regulated. Conclusion Troglitazone inhibits the growth of follicular thyroid carcinoma cells by arresting the G1/S phase transition, and troglitazone could be a choice for the treatment of the aggressive thyroid carcinoma.

关 键 词：甲状腺滤泡状癌细胞 曲格列酮 P27 

分 类 号：R736[医药卫生—肿瘤]